Steven E. Finkelstein, MD

home / authors / steven-e-finkelstein-md

Articles

$Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer$

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Chirag Shah, MD;Kevin Stephans, MD;Aditya Juloori, MD;Andrew Vassil, MD;Constantine Mantz, MD;Alvaro Martinez, MD;Frank Vicini, MD;Eduardo Fernandez, MD;Rahul D. Tendulkar, MD;Steven E. Finkelstein, MD

June 20th 2016

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Changes in Prostate Cancer Presentation for Radiation Oncology Care

Kevin W. Su, BS;Jane Hall, PhD;Rudi Ross, BS, CCRC;Pamela R. Soulos, MPH;Timothy D. Shafman, MD;James B. Yu, MD;Arie P. Dosoretz, MD;Daniel E. Dosoretz, MD;Steven E. Finkelstein, MD;Sharon Sa

October 3rd 2015

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Gustavo Olivera PhD;Xiaohu Mo MS;Don Parnell CMD;Stephanie Key CMD;Constantine Mantz, MD;Eduardo Fernandez MD, PhD;Daniel Dosoretz MD;Arie Dosoretz MD;Larry Kestin MD;Alvaro Martinez, MD;Steven E. Finkelstein, MD

June 13th 2015

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.